Anlotinib is a novel, multitargeted tyrosine kinase inhibitor that has activity against a range of RTKs involved in vascularization and tumor progression, including VEGFR-1, -2, and -3; FGFR-1, -2, -3, and -4; c-kit; and PDGFR-α and -β (Shen et al., 2018; Gao et al., 2020). Here, KIT is linked to neoplasm.